Present updated data from the BEAM-302 Phase 1/2 clinical trial
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 6 May 2025
- Due
- 31 Dec 2025
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Updated Data Expected to be Presented in Second Half of 2025”
What we found
Evidence strength A What the grades mean
The company did not present updated data for the BEAM-302 trial in the second half of 2025, instead announcing in early 2026 that it expected to report such data by the end of Q1 2026.
-
A Beam Therapeutics Inc. 10-K filed 2026-02-24
“We expect to report updated data from the trial and next steps for pivotal development by the end of the first quarter of 2026.” ✓ confirmed on the page
Market reaction: the shares moved +1.1% against the S&P 500 over the three sessions around the disclosure (23 Feb 2026 to 26 Feb 2026). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +252 days
- 2 versions
-
Version 1 · original · stated 6 May 2025
Deadline 31 Dec 2025 (“in Second Half of 2025”) · wording expected
-
Version 2 · stated 4 Aug 2026
Deadline 9 Sep 2026 (“September 5-9, 2026”)
“Detailed and updated clinical data for BEAM-302 were selected for a late-breaking oral presentation at the European Respiratory Society (ERS) Congress, taking place September 5-9, 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- BEAM-302 Phase 1/2 clinical trial data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-BEAM-003308 · Corrections policy